NCIt definition : An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate
3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity.
PI3K alpha inhibitor AZD8835 selectively binds to and inhibits PIK3CA and its mutated
forms, in the PI3K/Akt (protein kinase B) /mammalian target of rapamycin (mTOR) pathway.
This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells.
By specifically targeting PIK3CA, this agent may be more efficacious and less toxic
than pan-PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is often found
in solid tumors and results in the promotion of tumor cell growth, survival, and resistance
to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes,
encodes the p110-alpha catalytic subunit of the class I PI3K.;